College of American pathologists proposal for the oversight of laboratory-developed tests

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Context.-The US Food and Drug Administration (FDA) announced it will exercise authority over laboratorydeveloped tests (LDTs). Laboratory-developed tests have traditionally been developed and offered in laboratories as a service to patients and regulated under the Clinical Laboratory Improvement Amendments of 1988 (Clinical Laboratory Improvements Act). Laboratories now face potential dual regulatory oversight from both the Centers for Medicare and Medicaid Services (CMS) and the FDA. The College of American Pathologists (CAP) constructed a proposal to minimize redundancy of agency oversight and burden to laboratories. Modifications to the proposal continue while the laboratory community awaits release of the guidance documents that will stipulate FDA requirements. Objective.-To describe the historical context framing the entry of FDA into the oversight of LDTs and outline the CAP LDT Proposal in its current form. Data Sources.-PubMed review of published literature; United States Constitution; and online information resources from the National Institutes of Health, FDA, and US Government. Conclusion.-The College of American Pathologists is a leader in laboratory quality and has unique insights into the benefits and risks to patients presented by LDTs. Continued dialog with officials from the FDA and CMS will promote public and private collaborative efforts to assure innovation of diagnostic testing, public information, and patient safety for clinical diagnostic testing.

Original languageEnglish (US)
Pages (from-to)1432-1435
Number of pages4
JournalArchives of Pathology and Laboratory Medicine
Volume135
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

United States Food and Drug Administration
Centers for Medicare and Medicaid Services (U.S.)
Pathologists
Information Storage and Retrieval
Constitution and Bylaws
National Institutes of Health (U.S.)
Patient Safety
PubMed
Exercise

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

College of American pathologists proposal for the oversight of laboratory-developed tests. / Vance, Gail H.

In: Archives of Pathology and Laboratory Medicine, Vol. 135, No. 11, 01.11.2011, p. 1432-1435.

Research output: Contribution to journalArticle

@article{b35515860a6e445daa920f163eb7e717,
title = "College of American pathologists proposal for the oversight of laboratory-developed tests",
abstract = "Context.-The US Food and Drug Administration (FDA) announced it will exercise authority over laboratorydeveloped tests (LDTs). Laboratory-developed tests have traditionally been developed and offered in laboratories as a service to patients and regulated under the Clinical Laboratory Improvement Amendments of 1988 (Clinical Laboratory Improvements Act). Laboratories now face potential dual regulatory oversight from both the Centers for Medicare and Medicaid Services (CMS) and the FDA. The College of American Pathologists (CAP) constructed a proposal to minimize redundancy of agency oversight and burden to laboratories. Modifications to the proposal continue while the laboratory community awaits release of the guidance documents that will stipulate FDA requirements. Objective.-To describe the historical context framing the entry of FDA into the oversight of LDTs and outline the CAP LDT Proposal in its current form. Data Sources.-PubMed review of published literature; United States Constitution; and online information resources from the National Institutes of Health, FDA, and US Government. Conclusion.-The College of American Pathologists is a leader in laboratory quality and has unique insights into the benefits and risks to patients presented by LDTs. Continued dialog with officials from the FDA and CMS will promote public and private collaborative efforts to assure innovation of diagnostic testing, public information, and patient safety for clinical diagnostic testing.",
author = "Vance, {Gail H.}",
year = "2011",
month = "11",
day = "1",
doi = "10.5858/arpa.2011-0304-SA",
language = "English (US)",
volume = "135",
pages = "1432--1435",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "11",

}

TY - JOUR

T1 - College of American pathologists proposal for the oversight of laboratory-developed tests

AU - Vance, Gail H.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Context.-The US Food and Drug Administration (FDA) announced it will exercise authority over laboratorydeveloped tests (LDTs). Laboratory-developed tests have traditionally been developed and offered in laboratories as a service to patients and regulated under the Clinical Laboratory Improvement Amendments of 1988 (Clinical Laboratory Improvements Act). Laboratories now face potential dual regulatory oversight from both the Centers for Medicare and Medicaid Services (CMS) and the FDA. The College of American Pathologists (CAP) constructed a proposal to minimize redundancy of agency oversight and burden to laboratories. Modifications to the proposal continue while the laboratory community awaits release of the guidance documents that will stipulate FDA requirements. Objective.-To describe the historical context framing the entry of FDA into the oversight of LDTs and outline the CAP LDT Proposal in its current form. Data Sources.-PubMed review of published literature; United States Constitution; and online information resources from the National Institutes of Health, FDA, and US Government. Conclusion.-The College of American Pathologists is a leader in laboratory quality and has unique insights into the benefits and risks to patients presented by LDTs. Continued dialog with officials from the FDA and CMS will promote public and private collaborative efforts to assure innovation of diagnostic testing, public information, and patient safety for clinical diagnostic testing.

AB - Context.-The US Food and Drug Administration (FDA) announced it will exercise authority over laboratorydeveloped tests (LDTs). Laboratory-developed tests have traditionally been developed and offered in laboratories as a service to patients and regulated under the Clinical Laboratory Improvement Amendments of 1988 (Clinical Laboratory Improvements Act). Laboratories now face potential dual regulatory oversight from both the Centers for Medicare and Medicaid Services (CMS) and the FDA. The College of American Pathologists (CAP) constructed a proposal to minimize redundancy of agency oversight and burden to laboratories. Modifications to the proposal continue while the laboratory community awaits release of the guidance documents that will stipulate FDA requirements. Objective.-To describe the historical context framing the entry of FDA into the oversight of LDTs and outline the CAP LDT Proposal in its current form. Data Sources.-PubMed review of published literature; United States Constitution; and online information resources from the National Institutes of Health, FDA, and US Government. Conclusion.-The College of American Pathologists is a leader in laboratory quality and has unique insights into the benefits and risks to patients presented by LDTs. Continued dialog with officials from the FDA and CMS will promote public and private collaborative efforts to assure innovation of diagnostic testing, public information, and patient safety for clinical diagnostic testing.

UR - http://www.scopus.com/inward/record.url?scp=82555194532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82555194532&partnerID=8YFLogxK

U2 - 10.5858/arpa.2011-0304-SA

DO - 10.5858/arpa.2011-0304-SA

M3 - Article

C2 - 22032569

AN - SCOPUS:82555194532

VL - 135

SP - 1432

EP - 1435

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 11

ER -